Hospital Universitário Professor Edgard Santos
19
0
0
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
5.3%
1 terminated/withdrawn out of 19 trials
92.9%
+6.4% vs industry average
26%
5 trials in Phase 3/4
0%
0 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
ELECTRICAL STIMULATION AND EXERCISE FOR MUSCLE LOSS IN CIRRHOSIS PATIENTS
Role: lead
Sacubitril/Valsartan in Resistant Hypertension
Role: collaborator
Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1
Role: lead
Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly
Role: lead
Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis
Role: lead
Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
Role: lead
Miltefosine and GM-CSF in Cutaneous Leishmaniasis
Role: lead
Urological Physical Therapy in HTLV-1 With Urinary Symptoms
Role: lead
Electrostimulation PROTOCOL Incontinence
Role: lead
Autologous Bone Marrow Stem Cell Transplantation for Osteonecrosis in Sickle Cell Disease
Role: collaborator
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
Role: lead
High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus
Role: lead
Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases
Role: lead
Liposomal Amphotericin in Disseminated Leishmaniasis
Role: lead
A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder
Role: lead
Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine
Role: lead
Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)
Role: lead
Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis
Role: lead
Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis
Role: lead
All 19 trials loaded